Physician profile
Paula E Orr
NPI 1023047818
$752.47
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $75.46 · 2021: $143 · 2022: $33.34 · 2023: $116 · 2024: $90.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $206.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $209.73 | 2019-2021 | |
| Abbvie INC. | $76.65 | 2019-2022 | |
| Lupin INC. | $55.44 | 2019-2021 | |
| Hologic Sales and Service, LLC | $53.37 | 2021-2023 | Aptima, Thinprep 2000 Processor |
| Myovant Sciences INC. | $44.17 | 2021 | |
| Shield Therapeutics INC | $37.92 | 2023-2024 | Accrufer |
| Astellas Pharma US INC | $32.77 | 2023-2024 | Veozah |
| Revance Therapeutics, INC. | $31.68 | 2024 | Daxxify |
| Organon LLC | $31.28 | 2023 | Nexplanon |
| Merz North America, INC. | $24.81 | 2024 | |
| Azurity Pharmaceuticals, INC. | $23.98 | 2023 | Adthyza |
| Pfizer INC. | $21.57 | 2022 | |
| Amgen INC. | $20.26 | 2019 | |
| Evofem Biosciences, INC. | $17.94 | 2021 | |
| Radius Health, INC. | $16.77 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $15.27 | 2019 | |
| Exeltis, USA INC. | $13.95 | 2021 | |
| Merck Sharp & Dohme LLC | $12.64 | 2020 | |
| Allergan, INC. | $12.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Orr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.